A haplotype reference panel constructed from 490,319 UK Biobank genomes improves genotype imputation for global populations

By Wienbrandt, Prieß, Schmöhl +6Nature geneticsOct 30, 2026

Score█████░░░░░4.7

VerdictWorth a reader's time today.

Abstract

Here we constructed a genotype imputation reference panel from whole-genome sequencing data from 490,319 UK Biobank (UKB) participants1 and enabled both standalone and cloud-based phasing and imputation through EagleImp2 and EagleImp-RAP within the UK Biobank Research Analysis Platform. The UKB reference panel achieves lower phasing switch error rates than the widely used TOPMed r3 panel (133,597 individuals) for all global superpopulations except AMR and for 25 of 26 1000 Genomes Project subpopulations. Imputation accuracy, measured by MAE, improved for 4 of 5 superpopulations and 12 subpopulations for variants with minor allele frequencies down to 0.01%. Estimated squared correlation further improved across all 5 superpopulations and 22 subpopulations, with the largest gains in East and South Asian populations. Reimputation of COVID-19 genome-wide association study datasets from Italy, Germany, Spain and Norway3,4 demonstrated that common-variant imputation remains unsaturated, enhancing the discovery of genome-wide significant loci and improving fine-mapping resolution.

Lars Wienbrandt, Christoph Prieß, Marcus Schmöhl, Volker Neff, Maria Gretsova, Guillermo Torres, Eike Matthias Wacker, Andre Franke, David Ellinghaus

The editor's rubric

Heuristic review

Leverage3 / 5: A method or resource many groups across the field will adopt within a year.; 10% of this desk’s rubric
Magnitude2 / 5: Solid incremental gain on a meaningful problem.; 20% of this desk’s rubric
Evidence4 / 5: Strong: large scale, preregistered, independently replicated, or a well-powered randomized trial.; 32% of this desk’s rubric
Novelty3 / 5: A genuinely new approach to an open problem.; 8% of this desk’s rubric
Trajectory2 / 5: Some room to improve with obvious engineering.; 5% of this desk’s rubric
Stakes3 / 5: Meaningful benefit to many people within a few years.; 25% of this desk’s rubric

Dimension	Level	Weight	What that level means
Leverage	███░░3/5	10%	A method or resource many groups across the field will adopt within a year.
Magnitude	██░░░2/5	20%	Solid incremental gain on a meaningful problem.
Evidence	████░4/5	32%	Strong: large scale, preregistered, independently replicated, or a well-powered randomized trial.
Novelty	███░░3/5	8%	A genuinely new approach to an open problem.
Trajectory	██░░░2/5	5%	Some room to improve with obvious engineering.
Stakes	███░░3/5	25%	Meaningful benefit to many people within a few years.

Editor’s rationale

Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: breadth (programmable); novelty (discovery); stakes (global scale, major disease).

How the score was computed

rank-2026-10-18

Score█████░░░░░4.7

Score = 10 × (80% × adjusted merit / 10 + 10% × attention + 10% × freshness)

Desks place stronger verdicts first, then use this score to order work within the same verdict.

Merit: 6.1 / 10; Weighted rubric, evidence-gated.
Adjusted merit: 4.8 / 10; Shrunk toward the desk prior by editor confidence (38%).
Attention: 0%; Citations, upvotes, points, mentions.
Freshness: 85%; Half-life decay since publication.

Citations0 (reference 20, via openalex, Nov 1, 2026, 05:48 UTC)

The record

Reviewed by heuristic-v10 on Nov 1, 2026, 06:17 UTC. Paper type: empirical.
Categories: IM, Journal Article
BRIEF, No.6 in the Biology edition of November 1, 2026.